[Angiotensin and saluretics in nephrogenic diabetes insipidus of early infancy].
D000804:Angiotensin II / Q000627:therapeutic use*; D001831:Body Temperature; D002752:Chlorthalidone / Q000627:therapeutic use*; D003919:Diabetes Insipidus / Q000151:congenital* / Q000188:drug therapy; D004573:Electrolytes / Q000032:analysis; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006955:Hypernatremia / Q000628:therapy; D007231:Infant, Newborn; D007668:Kidney / Q000098:blood supply; D007684:Kidney Tubules / Q000002:abnormalities*; D012964:Sodium / Q000378:metabolism / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use; D013542:Sweat / Q000032:analysis
D004573:Electrolytes; D006852:Hydrochlorothiazide; D000804:Angiotensin II; D013148:Spironolactone; D005665:Furosemide; D012964:Sodium; D002752:Chlorthalidone
Angiotensin und Saluretika beim Diabetes insipidus renalis im frühen Säuglingsalter.